Synonyms: BLU 945 | BLU945 | Compound 150 [WO2021133809A1]
Compound class:
Synthetic organic
Comment: BLU-945 is a potent, non-covalent, and orally available EGFR inhibitor (4th generation, wild type-sparing), that was designed to inhibit the EGFR pathway and provide anti-tumour activity in NSCLC with EGFR resistance mutations (EGFR with T790M/C797S triple mutant that confers resistance to the 3rd generation EGFR inhibitor osimertinib). Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting, and this was matched by the Guide to PHARMACOLOGY team to one of the structures (compound 150) in Blueprint Medicines' patent WO2021133809A1 [1], and this association was confirmed by peer-reviewed publication of BLU-945's discovery in summer 2022 [2]. The chemical structure of BLU-945 matches that of the INN tigozertinib (proposed INN list 130, Feb. 2024).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Download 2D Structure ![]() |
|
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel